SCHEMBL1935238

SCHEMBL1935238

Cc1ccc(S(=O)(=O)n2ccc3nc(N(C)C(=O)[C@@H]4CCCN(C(=O)OC(C)(C)C)C4)cnc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.44
HTR6 P50406 2/20 0.39
BCHE P06276 1/20 0.39
ALDH1A1 P00352 4/20 0.37
POLB P06746 1/20 0.37
MMP13 P45452 3/20 0.36
MMP1 P03956 1/20 0.36
MMP9 P14780 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
GPR119 Q8TDV5 2/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
TGM2 P21980 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
ADAM17 P78536 1/20 0.35
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28589631 1.00 USP30 (0.44) USP30HTR6BCHEALDH1A1POLB
SCHEMBL9990716 0.93 HTR6 (0.38) USP30HTR6BCHEALDH1A1POLB
SCHEMBL1934086 0.93 HTR6 (0.38) USP30HTR6BCHEALDH1A1POLB
SCHEMBL28587650 0.89 ALDH1A1 (0.41) ALDH1A1POLBNPC1RAB9A
SCHEMBL4355056 0.89 USP30 (0.39) USP30HTR6MMP13GPR119TGM2
SCHEMBL1933877 0.89 USP30 (0.39) USP30HTR6MMP13GPR119TGM2
SCHEMBL1935172 0.84 GPR119 (0.39) USP30HTR6MMP13GPR119TGM2
SCHEMBL1935242 0.83 HTR6 (0.43) HTR6BCHEALDH1A1MMP13MMP1
SCHEMBL1934902 0.83 HTR6 (0.43) HTR6BCHEALDH1A1MMP13MMP1
SCHEMBL18832817 0.81 ALDH1A1 (0.39) ALDH1A1POLBNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3950692-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2022-02-09 EP disclosed
CN-109053742-B Novel tricyclic compounds ABBVIE 公司 2021-06-15 CN disclosed
US-20210061813-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2021-03-04 US disclosed
US-RE47221-E1 Tricyclic compounds ABBVIE INC. (US) 2019-02-05 US disclosed
EP-3266786-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2018-01-10 EP disclosed
EP-2506716-B1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2017-05-17 EP disclosed
US-20160222020-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-08-04 US disclosed
US-20130216497-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES 2013-08-22 US disclosed
US-8426411-B2 Tricyclic compounds ABBOTT LABORATORIES (US) 2013-04-23 US disclosed
EP-2506716-A1 NOVEL TRICYCLIC COMPOUNDS Abbott Laboratories (US) 2012-10-10 EP disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 US disclosed
WO-2011068881-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061813-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 USP30 4655/4885HTR6 1465/4885BCHE 3024/4885
US-20160222020-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 USP30 4655/4885HTR6 1465/4885BCHE 3024/4885
US-20110311474-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 USP30 4655/4885HTR6 1465/4885BCHE 3024/4885
US-20130216497-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 USP30 4655/4885HTR6 1465/4885BCHE 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.